NCT05013086View on ClinicalTrials.gov

177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

October 30, 2024

Study Completion Date

December 1, 2024

Conditions
Integrin αVβ3 Positive Tumors
Interventions
DRUG

1.48 GBq of 177Lu-AB-3PRGD2

accepted intravenous injection of 177Lu-AB-3PRGD2

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER